Wealthcare Advisory Partners LLC Makes New Investment in Abrdn Life Sciences Investors (NYSE:HQL)

Wealthcare Advisory Partners LLC bought a new stake in Abrdn Life Sciences Investors (NYSE:HQL) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,301 shares of the company’s stock, valued at approximately $131,000.

A number of other hedge funds have also recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its position in Abrdn Life Sciences Investors by 3.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company’s stock worth $395,000 after buying an additional 933 shares during the period. 180 Wealth Advisors LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 0.9% during the first quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company’s stock worth $1,727,000 after purchasing an additional 1,247 shares during the period. Kapstone Financial Advisors LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 11.0% during the fourth quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company’s stock worth $185,000 after purchasing an additional 1,300 shares during the period. BankPlus Trust Department bought a new stake in shares of Abrdn Life Sciences Investors in the fourth quarter worth $28,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in Abrdn Life Sciences Investors by 379.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock valued at $64,000 after purchasing an additional 3,847 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Stock Down 1.0%

Shares of NYSE:HQL opened at $12.86 on Monday. The business has a fifty day simple moving average of $12.27 and a 200 day simple moving average of $13.06. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90.

Abrdn Life Sciences Investors Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Thursday, May 22nd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 13.38%. The ex-dividend date of this dividend is Thursday, May 22nd.

Insider Activity at Abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $13.01, for a total transaction of $428,315.22. Following the completion of the transaction, the insider now owns 3,240,630 shares of the company’s stock, valued at $42,160,596.30. This trade represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 210,080 shares of company stock worth $2,565,065 over the last ninety days. Insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.